Achilles Therapeutics plc American Depositary Shares - ACHL STOCK NEWS

Achilles Therapeutics has been added to the NASDAQ Biotechnology Index effective December 20, 2021. This index tracks biotechnology and pharmaceutical securities on Nasdaq. To qualify, companies must meet specific criteria, such as market cap and trading volume. Achilles develops precision T cell therapies targeting unique cancer markers, with two ongoing Phase I/IIa trials: CHIRON for advanced non-small cell lung cancer and THETIS for melanoma. The press release includes forward-looking statements regarding future performance and risks involved.

Achilles Therapeutics (NASDAQ: ACHL) reported significant advancements at the ESMO Immuno-Oncology Congress 2021, showcasing a over 10-fold increase in clonal neoantigen-reactive T cell (cNeT) doses with their VELOS™ Process 2 manufacturing. This process has successfully transitioned to GMP-scale for clinical trials, maintaining critical T cell subsets. The company aims to commence high-dose patient dosing in the first half of 2022, with results from clinical trials expected by the second half of the same year.

Achilles Therapeutics (NASDAQ: ACHL) presented significant data at the Society for Immunotherapy of Cancer Annual Meeting. The company demonstrated the ability to detect and track patient-specific clonal neoantigen-reactive T cells (cNeT), enhancing dose generation from their VELOS™ Process 2 manufacturing method, achieving an 18-fold increase in cNeT compared to Process 1. Initial results from the ongoing Phase I/IIa clinical trials for melanoma and non-small cell lung cancer indicated stable disease in 63% of patients. The company will discuss these findings in a conference call today.

Secarna Pharmaceuticals has entered into a research, option, and license agreement with Achilles Therapeutics to develop optimized personalized T cell therapies in the field of immune oncology. Utilizing its LNAplus platform, Secarna will create antisense oligonucleotide (ASO) candidates targeting undisclosed cancer-related markers. Secarna will receive an undisclosed upfront payment, milestone payments, and tiered royalties from the collaboration. This partnership aims to combine Secarna's ASO expertise with Achilles' T cell therapy innovations, potentially enhancing cancer treatments.

Achilles Therapeutics plc (NASDAQ: ACHL) reported third-quarter financial results on November 9, 2021, showcasing a net loss of $12.9 million or $0.34 per share, an increase from $8.2 million or $7.50 per share a year prior. The company highlighted progress in its CHIRON and THETIS clinical trials, with the first US patient enrolled. Achieving higher doses of clonal neoantigen-reactive T cells from its VELOS™ Process 2 was emphasized at the SITC conference. Cash and equivalents stood at $281.9 million, sufficient to fund operations into 2023.

Achilles Therapeutics has joined the Northern Alliance for Advanced Therapies Treatment Centre consortium, funded by Innovate UK. This initiative aims to enhance the delivery of advanced therapy medicinal products, addressing challenges in clinical pathways from procurement to reimbursement. Achilles will leverage its expertise in supply chain management and cell therapy operations to identify gaps in current practices. The company is known for its precision T cell therapies targeting clonal neoantigens, currently undergoing Phase I/IIa trials for lung cancer and melanoma.

Achilles Therapeutics (NASDAQ: ACHL) will present an oral presentation and two posters at upcoming medical congresses. The 2021 ESGCT Congress will feature a presentation on October 22, focusing on a clonal neoantigen-reactive T cell therapy pipeline. Meanwhile, at the SITC 36th Annual Meeting on November 10-14, two posters will detail advancements in Clonal Neoantigen T cell (cNeT) therapies. Achilles specializes in precision T cell therapies targeting unique cancer markers. Upcoming details on abstracts and presentations will be released on specific dates.

Achilles Therapeutics plc (NASDAQ: ACHL) announced its participation in several investor conferences in September 2021. The presentations include the Wells Fargo Virtual Healthcare Conference on September 10, the H.C. Wainwright 23rd Annual Global Investment Conference starting September 13, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22. A webcast of the presentations will be available on the Achilles website.